Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Mabs|February 2, 2023
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapyChristina Claus, Claudia Ferrara-Koller, Christian Klein
Protein Engineering, Design & Selection : PEDS|September 1, 2016
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functionsTilman Schlothauer, Sylvia Herter, Claudia Ferrara Koller, et al.
Mabs|July 25, 2019
Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeuticsOksana Tyshchuk, Christoph Gstöttner, Dennis Funk, et al.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 25, 2025
Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphomaZeno Riester, Marlena Surowka, Nicole Seifert, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
Molecular Cancer Therapeutics|April 3, 2016
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell ApoptosisPeter Brünker, Katharina Wartha, Thomas Friess, et al.
Pageof 1